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B.J. Manning,* N. Hynes, D.F. Courtney and S. SultanVascular and Endovascular Surgery Department, University College Hospital Galway, Newcastle Road,
Galway, IrelandIntractable bleeding unresponsive to conventional haemostatic measures is an uncommon but potentially life threatening
surgical complication. Several studies have suggested that recombinant factor VIIa (rVIIa), a genetically engineered
substitute for endogenous factor VIIa may have therapeutic application in patients with uncontrollable haemorrhage not
previously diagnosed with coagulopathy. We report our experience of rVIIa use in eight such vascular surgery patients who
developed life-threatening non-surgical haemorrhage either intra-operative or post-operatively. In all but one patient a
marked clinical improvement was noted following treatment with rVIIa with significantly less transfusion, and obvious
haemostasis associated with haemodynamic stability without adverse thrombotic complications.Keywords: Recomdinant factor VIIa; Haemorrhage; Haemostasis.Introduction
A recombinant form of activated factor VII (rVIIa) has
become standard treatment of bleeding in patients
with factor VIII of factor XI deficiency (haemophiliacs)
or inhibitors to these factors.1 There is a growing body
of evidence which shows rVIIa to be of benefit and
potentially life-saving in patients with bleeding not
related to previous coagulation abnormalities.2 This
intractable ‘non-surgical’ bleeding cannot usually be
attributable to a single or a small number of bleeding
vessels. We report our experience of the use of rVIIa in
vascular surgery patients who develop intra-operative
or post-operative life threatening haemorrhage unre-
sponsive to conventional haemostatic measures.Report
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rVIIa. This off label use was agreed on a individual
basis on compassionate grounds similar to its use in
previous studies.2,3 Informed consent was obtained
from all patients presenting for major vascular
procedures for the possible use of rVIIa. The decision
to administer rVIIa at the time of surgery was made in
cases where hypotension and anaemia were associated
with generalised ooze in the operative field, in the
absence of a major arterial bleed. A dose of 40 mg/kg
was administered as a bolus injection over 2 min,
repeated once depending on the clinical response. Full
blood count and coagulation profile were measured
prior to and after rVIIa administration. Blood product
administration, haemodynamic profile, peri-operative
course and outcome were all recorded retrospectively
(Table 1).
Of 310 patients who underwent major vascular
reconstruction in the study period, eight developed
life threatening haemorrhage unresponsive to conven-
tional haemostatic measures either intra-operatively
(six patients) or post-operatively (two patients), and
met with our criteria for treatment with rVIIa. Clinical
improvement was reported following treatment in
seven of eight patients in the study. Bleeding wasEur J Vasc Endovasc Surg 30, 525–527 (2005)
doi:10.1016/j.ejvs.2005.06.021, available online at http://www.sciencedirect.com onved.
Table 1. Patients details
Patient Age Sex Surgery Emergency rVIIa dose/kg
(mg)
Improvement
1 80 F Juxtarenal AAA repair Yes 40 Yes
2 77 M Suprarenal AAA repair Yes 80 Yes
3 79 F Juxtarenal AAA repair No 80 Yes
4 77 F Suprarenal AAA repair No 80 No
5 56 M Excision of infected aortic
graft
No 80 Yes
6 75 M Juxtarenal AAA repair retro-
peritoneal bleed*
No 40 Yes
7 82 M EVAR internal iliac aneurysm
ligation. Retroperitoneal
bleed†
No 40 Yes
8 66 F Pelvic fracture with major
vascular trauma‡
Yes 40 Yes
AAA, abdominal aortic aneurysm; EVAR, endovascular aneurysm repair.
* Developed a retroperitoneal haematoma 12 day post-operatively.
† Developed a retroperitoneal haematoma several hours post-operatively which was explored with insertion of a suction drain in the area
of non-surgical haemorrhage.
‡ Unstable pelvic fracture treated with external fixation. External iliac artery and common illiac vein and superficial femoral vein trauma
treated with covered stent insertion and groin exploration.
B. J. Manning et al.526successfully controlled as evidenced by improved
haemodynamic parameters and decreased inotrope
and transfusion requirement (Table 2). There was one
intra-operative death (patient 4), where rVIIa did not
have any visible effect on non-surgical haemorrhage.
A further patient (patient 3) remained inotrope-
dependent post-operatively despite haemodynamic
stability, and died on the first post-operative day. Post-
mortem examination did not report any evidence of
acute thrombotic events in either case.Discussion
The absence of a prospective randomised trial of the
use of rVIIa in patients with life threatening haemor-
rhage is perhaps not surprising given the difficulty in
identifying objective outcome parameters which
would be independent of the many other variables in
the treatment of bleeding and the ethical consider-
ations implicit in withholding a potentially life-saving
treatment with a low adverse side effect profile. The
successful arrest of haemorrhage in seven of the eight
patients treated with rVIIa cannot be attributed solelyTable 2. Blood production transfusion and coagulation parameters
Pre-rVIIa
PRBCs 8.13G2.0*
FFP 4 (0–15)†
INR 1.2 (1–1.5)†
APTT 38.3 (30–205)†
PRBCs, packed red blood cells; FFP, fresh frozen plasma; INR, internati
* Values are meanGs.e.m., (Student t-test).
† Values are median (range), (Mann–Whitney test).
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coincided with blood product transfusion, as well as
surgical cauterisation and aggressive measures to
correct hypothermia and metabolic acidosis. However,
in patients 1, 2, 3 and 5 an obvious reduction in the
generalized ooze in the operative field was noted
within minutes of rVIIa administration. Patient 6
developed a retroperitoneal haematoma following
dialysis treatment 12 days post-operatively with
associated haemodynamic instability. Systolic blood
pressure increased from 85 to 130 mmHg within
minutes of rVIIa administration, without the need
for continued blood transfusion. Patient 7 underwent
endovascular stenting of an infra-renal aortic aneur-
ysm with open ligation of an aneurysmal internal iliac
artery. A post-operative retroperitoneal haematoma
was evacuated and a suction drain inserted which
yielded 780 ml of blood over the subsequent 10 h.
rVIIa was administered to good effect with drainage
decreasing to 208 ml over a subsequent 10 h period.
The low risk of thrombotic complications of rVIIa is
borne out by experience in haemophiliacs and the
limited reports from non-coagulopathic patients
where the risk is estimated at less than 1%. We foundPost-rVIIa P-value
3.2G1.1* 0.05
0 (0–2)† 0.003
1.2 (0.8–3.1)† 0.33
38.7 (29–190)† 0.65
onal normalizing ratio; APTT, activated partial thromboplastin time.
Recombinant Factor Vlla and Haemostasis 527a dose or 40–80 mg to be effective for most patients,
lower than the dose recommended for those with
haemophilia-associated inhibitors.4 Dosage was based
on clinical response, rather than on measured coagu-
lation parameters, which we did not differ signifi-
cantly before and after rVIIa administration.
Only three patients received more than 8 units of
RCC in total. Similar to the experience of others5 we
observed that rVIIa is more likely to be therapeutic if
given as soon as an uncontrollable non-surgical
bleeding is encountered and least effective in patients
who had already received massive transfusion
volumes prior to its administration.
Although the high cost of the treatment, as well as
the small but real association with thrombotic
complications, necessitates a highly selective use of
rVIIa, our experience of its use in vascular surgery
patients with life threatening non-surgical haemor-
rhage is that it can produce a marked improvement in
haemostasis, with obvious clinical improvement,haemodynamic stability, and reduced blood product
requirement.References
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